Maria Aparecida Zanichelli

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Hagop M. Kantarjian, Timothy P. Hughes, Richard A. Larson et al. · Leukemia · 2021 · 351 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +7

Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients

A. L. Oliveira, M. de Souza, Viviane Maria Hessel Carvalho-Dias et al. · Bone Marrow Transplantation · 2007 · 168 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +14

Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis

Raquel Tognon, Elainy PL Gasparotto, Renata Peres Neves et al. · Journal of Hematology & Oncology · 2012 · 50 citations · Full text

Life Sciences, Genetics, Hematology +17

Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia

Luciene Terezina de Lima, Douglas Vivona, Carolina Tosin Bueno et al. · Medical Oncology · 2014 · 40 citations · Full text

Medicine, Molecular Biology, Oncology +10

ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib

Douglas Vivona, Carolina Tosin Bueno, Luciene Terezina de Lima et al. · Blood Cells Molecules and Diseases · 2011 · 39 citations · Full text

Medicine, Hematology, Oncology +6